Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Acalabrutinib + AZD0466 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD0466 | AZD-0466|AZD 0466 | BCL-XL inhibitor 14 BCL2 inhibitor 27 | AZD0466 is a nanoparticle comprised of the BH3 mimetic AZD4320 linked to a pegylated poly-lysine dendrimer, which is cleaved to release AZD4320, leading to inhibition of BCL-XL and BCL2, and potentially resulting in increased tumor cell apoptosis and decreased tumor growth (PMID: 34050131). | |
Acalabrutinib | Calquence | ACP-196 | BTK inhibitor 37 | Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|